Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

CV Therapeutics advances CVT-510 into phase II clinical trials

Dec. 10, 1999

Preparation and use of inhibitors of sodium-dependent Cl-/HCO3- exchange

Dec. 8, 1999

Chiron and Scios complete FGF agreement

Dec. 8, 1999

New cardioselective K(ATP) channel blocker inhibits ventricular fibrillation in ischemic rat model

Dec. 6, 1999

Highly potent inhibitor of PDGF-induced SMC proliferation discovered at Japan Energy

Dec. 3, 1999

Wakunaga identifies potent and selective chymase inhibitor

Dec. 3, 1999

Chiron and Searle plan pivotal phase III trial for sepsis compound

Dec. 3, 1999

Studies using new transgenic rat model illustrate role of CETP in atherosclerosis

Dec. 2, 1999

Kyowa Hakko prepares antiproliferative agents that interact with the PDGF receptor

Dec. 2, 1999

V1A/AT1 receptor antagonist combinations for cardiovascular disorders

Dec. 2, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...